STRIATAL OPIOID RECEPTOR-BINDING IN PARKINSONS-DISEASE, STRIATONIGRAL DEGENERATION AND STEELE-RICHARDSON-OLSZEWSKI SYNDROME - A [C-11] DIPRENORPHINE PET STUDY
STRIATAL OPIOID RECEPTOR-BINDING IN PARKINSONS-DISEASE, STRIATONIGRAL DEGENERATION AND STEELE-RICHARDSON-OLSZEWSKI SYNDROME - A [C-11] DIPRENORPHINE PET STUDY
复制标题
DOI：
10.1093/brain/118.4.951
复制
发表时间：
1995-08-01
期刊：
影响因子：
14.5
通讯作者：
BROOKS, DJ
中科院分区：
文献类型：
--
作者：
BURN, DJ;RINNE, JO;BROOKS, DJ
帕金森病与纹状体黑质变性（SND）型多系统萎缩（MSA）和Steele-Richardson-Olszewski综合征（SRO）的临床鉴别可能很困难。这反映在生活中被标记为“帕金森病”的临床病理学系列病例中的20-25%误诊率。尾状核和壳核含有高密度的阿片能神经元和受体，其与多巴胺能系统具有密切的解剖和生理关系。我们使用[C-11]二丙诺啡与PET研究了临床定义的帕金森病（n = 8），SND（n = 7）和SRO（n = 6）患者组与正常对照组（n = 8）相比，纹状体阿片受体结合。与正常人相比，帕金森病患者壳核和尾状核的平均配体结合率没有显着差异。平均壳核，但不是尾状核，阿片受体结合显着减少，在SND组，与正常相比。相比之下，在SRO组中，与正常组和帕金森病组相比，平均尾状核和壳核阿片受体结合均显著降低。当考虑个体患者时，八个帕金森病病例中没有一个（0%），七个SND病例中没有一个（0%），但是六个SRO病例中的四个（67%）具有比正常平均值低> 2.5SD的尾状阿片受体结合。壳核阿片受体结合的相应数字为：无帕金森病病例（0%）; 3例SND病例（43%）;所有SRO病例（100%）。我们的结论是，在帕金森病，SND和SRO患者的纹状体阿片受体结合的模式存在差异，由[C-11]二丙诺啡PET确定。不同的结合模式可能有助于区分这些运动不能刚性综合征在生活中。
The clinical differentiation of Parkinson's disease from the striatonigral degeneration (SND) type of multiple system atrophy (MSA) and Steele-Richardson-Olszewski syndrome (SRO) may be difficult. This is reflected by a 20-25% misdiagnosis rate in clinicopathological series of cases labelled as 'Parkinson's disease' in life. The caudate and putamen contain a high density of opioidergic neurons and receptors which have a close anatomical and physiological relationship with the dopaminergic system. We used [C-11]diprenorphine with PET to investigate striatal opioid receptor binding in groups of patients with clinically defined Parkinson's disease (n = 8), SND (n = 7) and SRO (n = 6), compared with normal controls (n = 8). There was no significant difference between mean ligand binding in the putamen and caudate of Parkinson's disease cases when compared with normals. Mean putamen, but not caudate, opioid receptor binding was significantly reduced in the SND group, when compared with normals. By contrast, in the SRO group, both mean caudate and putamen opioid receptor binding was significantly reduced when compared with both normal and Parkinson's disease groups. When considering the individual patients, none of the eight Parkinson's disease cases (0%), none of the seven SND cases (0%), but four of the six SRO cases (67%) had caudate opioid receptor binding that was >2.5 SDs below the normal mean. Corresponding figures for putamen opioid receptor binding were: none of the Parkinson's disease cases (0%); three of the SND cases (43%); and all of the SRO cases (100%). We conclude that there are differences in the pattern of opioid receptor binding in the striatum of Parkinson's disease, SND and SRO patients, as determined by [C-11]diprenorphine PET The different binding patterns may help to differentiate these akinetic-rigid syndromes in life.